UK Cannabis News & Industry Insights
Cannabis Insider
Prescription cannabis, NHS developments, and patient access in the UK.
Ananda Pharma has dosed the first patient in its Phase 2 ACTiON trial testing MRX1, a proprietary CBD medicine, for chemotherapy-induced peripheral neuropathy.
A US Phase 2 study presented in London found a purified THC and CBD oil sharply reduced agitation in hospice-eligible dementia patients — but researchers warn it is not the same as shop-bought cannabis products.
New Zealand producer Rua Bioscience has agreed to supply medical cannabis flower to one of the UK's largest private clinic and distribution groups, in a two-year deal worth more than NZ$10 million.
Research in The Journal of Physiology finds obese mice lost weight on both THC and whole-plant cannabis extract — but only the full extract improved blood sugar control, hinting that non-THC compounds may matter for metabolism.
Research in BMJ Mental Health using UK Biobank and US veteran data finds cannabis use in older adults is not associated with faster cognitive decline or higher dementia risk — though scientists warn heavy, long-term use remains poorly understood.
UK clinic Releaf has registered as a fully integrated GP practice, allowing it to prescribe standard BNF medicines for the significant share of patients who complete triage but are not eligible for medical cannabis.
Research published in the Journal of Workplace Behavioral Health links medical cannabis laws to a 6.9% drop in health-related absenteeism, with manual workers seeing the sharpest reductions.